The USFDA has approved Teprotumumab-trbw for the treatment of thyroid eye disease in adults. The drug has received 2 designations namely, Breakthrough Therapy and Orphan Drug since it is the first drug approved for the treatment of the disease. Introduction: Thyroid Eye Disease (TED) , also known as Graves Eye Disease is a rare disorder where the muscles and fatty tissues behind the eye become inflamed resulting in outward bulging of the eyes ( proptosis ).
The characteristic symptoms of the condition include eye pain, double vision, light sensitivity or difficulty closing the eyes. The troubled ocular symptoms lead to the inability to perform daily activities it leads to the inability to perform daily activities and hampers patient’s quality of life. Evidence-based study: Study Objective To investigate the efficacy, safety, and tolerability of the drug in patients suffering from active…
